Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) ...

PE: What impact will DTC programs have on generic drug prices? O’Dell: Not much today, but generics are not completely immune ...

Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license ...

Zag Bio announced the company’s launch with a $80 million financing round, which includes a recently closed Series A ...

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to ...

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Organon announced that CEO Kevin Ali intends to resign from his position following results from an internal investigation ...

PE: What impact will DTC programs have on generic drug prices? O’Dell: Not much today, but generics are not completely immune ...

Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...

Obesity is a complex, treatable medical condition, not just a matter of willpower, requiring a shift in perception and ...